A new report from the European Centre for Disease Prevention and Control indicates that universal immunization of newborns against respiratory syncytial virus could significantly reduce infant hospitalizations across the EU. The findings come as the RSV season approaches, with evidence showing national programs using nirsevimab or maternal vaccination are associated with large reductions in infant hospitalizations.
Endeavor BioMedicines announced that its WHISTLE-PF phase 2b trial of taladegib met its primary endpoint, demonstrating statistically significant improvement in lung function (ppFVC) compared to placebo in patients with IPF. The company claims the drug has potential to reverse disease course, unlike current therapies that only slow progression.
The weekly podcast from Texas Tech University features discussion of a new therapeutic target for asthma and chronic obstructive pulmonary disease, along with other top medical stories. The podcast is co-hosted by Elizabeth Tracey of Johns Hopkins Medicine and Dr. Rick Lange of Texas Tech Health El Paso.
AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.
AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.